BioSpace News Archive

Eli Lilly and Company provided an update on the company’s clinical trial activities in light of the COVID-19 pandemic.

Amicus Therapeutics announced that the Company has proactively taken numerous measures in response to the novel coronavirus pandemic to support the rare disease community globally and to ensure the achievement of its 2020 key strategic priorities.

Seres Therapeutics, Inc. announced the appointment of Paul Biondi, Executive Partner at Flagship Pioneering, to its Board of Directors.

Bristol-Myers Squibb Company announced that due to the ongoing COVID-19 pandemic, it will reschedule its planned April 2, 2020 Investor Day for a later date.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA (lumateperone) is now available to pharmacies in the U.S

With the emergence of COVID-19 has come tremendous global concern and uncertainty.

Arch Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) provided clearance to market AC5 ® Topical Gel that is manufactured using an additional supplier and additional manufacturing processes. AC5 Topical Gel is to be used in the management of partial and full-thickness wounds, such as pressu

Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced that on March 19, 2020, the Company closed on its previously announced private offering of common stock and warrants resulting in gross proceeds to the Company of $3,498,612.

Tetra Bio-Pharma Inc . ( today would like to announce that it has ensured that all of its employees work under conditions that comply with federal and provincial public health recommendations. Additionally, following the completion of its $17.8 M financing in February and early March, the Company is in a good position to maintain it

ProFound AI can assist radiologists in prioritizing patients for breast cancer screening and address the growing mammography backlog